SkinBioTherapeutics (LON:SBTX) Sets New 52-Week High – Should You Buy?

SkinBioTherapeutics plc (LON:SBTX) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as GBX 19.06 ($0.24) and last traded at GBX 18.85 ($0.24), with a volume of 2420459 shares changing hands. The stock had previously closed at GBX 17.75 ($0.22).

SkinBioTherapeutics Stock Up 6.2 %

The company has a current ratio of 6.57, a quick ratio of 10.01 and a debt-to-equity ratio of 2.66. The company has a market capitalization of £42.62 million, a price-to-earnings ratio of -887.50 and a beta of 2.01. The company has a 50-day moving average of GBX 14.06 and a 200-day moving average of GBX 12.01.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.